K
v
ire
.com
←
Back
Night
Docs
Library
Review
…
Author
Jörge E. Cortes
also known as Cortes, J., Cortes, J. E., Cortes, Jorge
Augusta University Health · South Australia Pathology · Goethe University Frankfurt · University of Maryland, Baltimore
About this author
Works
3,565
Cited by
143,742
h-index
180
i10
1495
ORCID ↗
Top papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, et al.
·
2022
·
Blood
↗ 2,559
OA
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani, Michael Deininger, Gianantonio Rosti, et al.
·
2013
·
Blood
↗ 1,985
Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias
Moshe Talpaz, Neil P. Shah, Hagop M. Kantarjian, et al.
·
2006
·
New England Journal of Medicine
↗ 1,769
OA
A Tyrosine Kinase Created by Fusion of the <i>PDGFRA</i> and <i>FIP1L1</i> Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome
Jan Cools, Daniel J. DeAngelo, Jason Gotlib, et al.
·
2003
·
New England Journal of Medicine
↗ 1,694
OA
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hagop M. Kantarjian, Neil P. Shah, Andreas Hochhaus, et al.
·
2010
·
New England Journal of Medicine
↗ 1,577
Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
Hagop M. Kantarjian, Francis J. Giles, Lydia Wunderle, et al.
·
2006
·
New England Journal of Medicine
↗ 1,341
OA
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani, Jörge E. Cortes, Fabrizio Pane, et al.
·
2009
·
Journal of Clinical Oncology
↗ 1,298
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
Alexander E. Perl, Giovanni Martinelli, Jörge E. Cortes, et al.
·
2019
·
New England Journal of Medicine
↗ 1,210
OA
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
Srđan Verstovšek, Hagop M. Kantarjian, Ruben A. Mesa, et al.
·
2010
·
New England Journal of Medicine
↗ 1,163
OA
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Jörge E. Cortes, D. W. Kim, Javier Pinilla‐Ibarz, et al.
·
2013
·
New England Journal of Medicine
↗ 1,117
OA
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Jeffrey E. Lancet, Geoffrey L. Uy, Jörge E. Cortes, et al.
·
2018
·
Journal of Clinical Oncology
↗ 981
OA
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
Michael J. Keating, Susan O’Brien, Maher Albitar, et al.
·
2005
·
Journal of Clinical Oncology
↗ 949
OA